A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE005 (FRA) · Dr. Muller
consented 2022-05-13
AEs
3
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-08-27 (study day 88); relationship: not assessed
mild
assessed
Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-12-29 (study day 212); relationship: not assessed
mild
assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-03-18 (study day 291); relationship: not assessed
Data queries
No data queries.